Proline sulfonamide derivatives as orexin receptor antagonists
View Patent ↗The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R 1 and R 2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
1. A method for attenuating a stress response in a subject, comprising administering to the subject in need thereof the compound (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide.
2. The method according to claim 1 , wherein said method comprises attenuating the acute behavioral and/or autonomic nervous system response to stress.
3. The method according to claim 1 , wherein said method comprises attenuating stress-associated arousal and/or vigilance in the subject.
4. The method according to claim 1 , wherein the stress is selected from psychological stress and physiological stress.
5. The method according to claim 3 , wherein the stress is selected from psychological stress and physiological stress.
6. The method according to claim 1 , wherein the stress is an acute stress.
7. The method according to claim 3 , wherein the stress is an acute stress.
8. The method according to claim 5 , wherein the stress is an acute stress.
9. The method according to claim 1 , wherein said subject has an anxiety disorder.
10. The method according to claim 9 , wherein the anxiety disorder is selected from the group consisting of a generalized anxiety disorder (GAD), an obsessive compulsive disorder (OCD), an acute stress disorder, a posttraumatic stress disorder (PTSD), a panic anxiety disorder (PAD), a phobic anxiety (PHOB), a specific phobia, a social anxiety disorder, avoidance, a somatoform disorder, a separation anxiety disorder, an anxiety disorder due to a general medical condition, and a substance induced anxiety disorder.
11. The method according to claim 1 , wherein said subject has a stress induced anxiety disorder.
12. The method according to claim 11 , wherein the anxiety disorder is selected from the group consisting of an acute stress disorder, a posttraumatic stress disorder (PTSD), a phobic anxiety (PHOB), a specific phobia, a social anxiety disorder, and a separation anxiety disorder.
13. The method according to claim 11 , wherein said subject has an anxiety-disorder associated with a defined traumatic event selected from the group consisting of an acute stress disorder and a separation anxiety disorder.
14. The method according to claim 1 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.
15. The method according to claim 2 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.
16. The method according to claim 3 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.
17. The method according to claim 7 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.
18. The method according to claim 11 , wherein said compound is (S)-1-(4-Methoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid (3,5-dimethyl-phenyl)-amide in free form.
19. The method according to claim 1 , wherein said compound is administered in the form of a pharmaceutical composition.
20. The method according to claim 2 , wherein said compound is administered in the form of a pharmaceutical composition.
21. The method according to claim 3 , wherein said compound is administered in the form of a pharmaceutical composition.
22. The method according to claim 7 , wherein said compound is administered in the form of a pharmaceutical composition.
23. The method according to claim 11 , wherein said compound is administered in the form of a pharmaceutical composition.
24. The method according to claim 19 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier.
25. The method according to claim 20 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier.
26. The method according to claim 21 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier.
27. The method according to claim 22 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier.
28. The method according to claim 23 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier.
29. The method according to claim 24 , wherein said pharmaceutical composition is in the form of a tablet.
30. The method according to claim 24 , wherein said pharmaceutical composition is in the form of a capsule.